Budesonide As a Treatment for Functional Dyspepsia

Last updated: February 17, 2025
Sponsor: Universitaire Ziekenhuizen KU Leuven
Overall Status: Active - Recruiting

Phase

4

Condition

Non-ulcer Dyspepsia (Nud)

Colic

Gastroparesis

Treatment

Mannitol

budesonide

Clinical Study ID

NCT06841406
S64291
  • Ages 18-70
  • All Genders

Study Summary

This clinical study is being conducted to evaluate the investigational drug, Budesonide, for the treatment of functional dyspepsia. The goal of this study is to learn more about the effect of Budesonide on patients with functional dyspepsia. Budesonide is a well-known and commonly used drug, and is part of the recommended therapy for patients with inflammatory bowel diseases (Crohn's disease or ulcerative colitis). It is also used as inhalation therapy for respiratory conditions such as asthma and COPD. However, the effect of Budesonide in patients with functional dyspepsia is still unknown. In patients with functional dyspepsia, an increased presence of inflammatory cells has been observed in the duodenum. Budesonide may reduce inflammatory responses.

Therefore, with this study, the investigators aim to investigate primarily:

  1. Whether Budesonide has an effect on the inflammatory cells observed in functional dyspepsia.

  2. Whether the symptoms of patients with functional dyspepsia improve during and after taking Budesonide.

  3. Whether inflammatory cells could be the cause of symptoms in functional dyspepsia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients with Functional dyspepsia (subtype postprandial distress syndrome) as perRome IV diagnostic criteria
  • Symptom characteristics of dyspepsia (upper gastrointestinal symptoms occurringin the last 3 months and meal related)

  • Negative endoscopy (maximum 12 months old)

  1. Patients must provide witnessed written informed consent prior to any studyprocedures being performed

  2. Patients aged between 18 and 70 years inclusive

  3. Male or female patients

  4. Women of child-bearing potential agree to apply a highly effective method of birthcontrol during the entire duration of the trial. Highly effective birth control isdefined as those which result in a low failure rate (i.e., less than 1% per year)when used constantly and correctly such as implants, injectables, combined oralcontraceptive method, or some intrauterine devices (IUDs), sexual abstinence, orvasectomized partner. Women of non-childbearing potential may be included ifsurgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses

  5. Subjects who are capable to understand the study and the questionnaires, and tocomply with the study requirements

Exclusion

Exclusion Criteria:

  1. Patients with any condition which, in the opinion of the investigator, makes thepatient unsuitable for entry into the study

  2. Patients with any major psychiatric disorders (including those with a majorpsychosomatic element to their gastrointestinal disease), depression, alcohol orsubstance abuse in the last 2 years

  3. Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) orof gastro-esophageal reflux disease (GERD)

  4. Presence of diabetes mellitus, celiac disease (diagnosed with presence ofanti-tissue transglutaminase antibodies and anti-gliadin antibodies or via duodenalbiopsies), lupus, scleroderma or other systemic auto-immune disease

  5. Patients with eosinophilic esophagitis or eosinophilic gastroenteritis

  6. Active H. Pylori infection (or < 6 months after eradication)

  7. Organic gastro-intestinal disease of history of gastrointestinal surgery other thanappendectomy

  8. Known impaired liver dysfunction

  9. Drugs altering gastric emptying, anti-inflammatory drugs, acid suppressive drugs orsome drugs altering the CYP3A4 metabolism

  10. Major change in diet last 3 months

  11. Females who are pregnant or lactating

  12. Patients not capable to understand or be compliant with the study

Study Design

Total Participants: 56
Treatment Group(s): 2
Primary Treatment: Mannitol
Phase: 4
Study Start date:
May 01, 2024
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • UZ Leuven

    Leuven, 3000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.